Nonalcoholic fatty liver disease: What do we know and what will we have to learn?
- 作者: Volkova N1, Porksheyan M1
-
隶属关系:
- Ростовский государственный медицинский университет Минздрава России
- 期: 卷 89, 编号 2 (2017)
- 页面: 91-98
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/32225
- DOI: https://doi.org/10.17116/terarkh201789291-98
- ID: 32225
如何引用文章
全文:
详细
The article reviews relevant data on the prevalence, natural history, pathogenesis, diagnosis, and treatment of nonalcoholic fatty liver disease and critically assesses the fixed notion of this disease.
作者简介
N Volkova
Ростовский государственный медицинский университет Минздрава РоссииРостов-на-Дону, Россия
M Porksheyan
Ростовский государственный медицинский университет Минздрава РоссииРостов-на-Дону, Россия
参考
- Williams CD, Stengel J, Asike MI et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124. doi: 10.1053/j.gastro.2010.09.038
- Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol Ther. 2011;4:274. doi: 10.1111/j.1365-2036.2011.04724.x
- Lazo M, Hernaez R, Eberhardt MS et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol. 2013;178:38. doi: 10.1093/aje/kws448
- Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434. doi: 10.1016/s0025-6196(11)64621-1
- Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol. 1989;20:594. doi: 10.1016/0046-8177(89)90249-9
- Powell EE, Cooksley WG, Hanson R et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11:74. doi: 10.1016/j.jhep.2004.02.013
- Diehl AM, Goodman Z, Ishak KG. Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology. 1988;95:1056. doi: 10.1111/j.1572-0241.2000.02748.x
- Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107:1103. doi: 10.1016/0270-9139(95)90482-4
- Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917. doi: 10.1053/jhep.2003.50161
- Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990;12:1106. doi: 10.1002/hep.1840120505
- Marchesini G, Brizi M, Morselli-Labate AM et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107:450. doi: 10.1016/s0002-9343(99)00271-5
- Cello JP, Grendell JH. The liver in systemic conditions. In: Hepatology. Zakim D, Boyer TD, eds. Philadelphia: WB Saunders; 1990:1428. doi: 10.1016/0270-9139(91)90240-v
- Pinto HC, Baptista A, Camilo ME et al. Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci. 1996;41:172. doi: 10.1007/bf02208601
- Itoh S, Yougel T, Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol. 1987;82:650. doi: 10.1111/j.1530-0277.2008.00755.x
- Fracanzani AL, Valenti L, Bugianesi E et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48:792. doi: 10.1002/hep.22429
- Naga Chalasani, Zobair Younossi, Joel E. Lavine, Anna Mae Diehl, Elizabeth M. Brunt, Kenneth Cusi, Michael Charlton, Arun J. Sanyal. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association or the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012;107:811-826. doi: 10.1038/ajg.2012.128
- White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342. doi: 10.1016/j.cgh.2012.10.001
- Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol. 2009;51:371. doi: 10.1016/j.jhep.2009.03.019
- Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356. doi: 10.1002/hep.510300604
- Ratziu V, Giral P, Charlotte F et al. Liver fibrosis in overweight patients. Gastroenterology. 2000;118:1117. doi: 10.1016/s0016-5085(00)70364-7
- Noureddin M, Yates KP, Vaughn IA et al. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology. 2013;58:1644. doi: 10.1002/hep.26465
- Hossain N, Afendy A, Stepanova M et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1224. doi: 10.1016/j.cgh.2009.06.007
- Francque SM, Verrijken A, Mertens I et al. Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. Clin Gastroenterol Hepatol. 2012;10:1162. doi: 10.1016/j.cgh.2012.06.019
- Matteoni CA, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413. doi: 10.1016/s0016-5085(99)70506-8
- Petta S, Amato MC, Di Marco V et al. Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2012;35:238. doi: 10.1111/j.1365-2036.2011.04929.x
- Molloy JW, Calcagno CJ, Williams CD et al. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology. 2012;55:429. doi: 10.1002/hep.24731
- Lazo M, Hernaez R, Bonekamp S et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ. 2011;343:d6891. doi: 10.1136/bmj.d6891
- Ekstedt M, Franzén LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865. doi: 10.1002/hep.21327
- Rafiq N, Bai C, Fang Y et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7:234. doi: 10.1016/j.cgh.2008.11.005
- Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol. 2008;49:608. doi: 10.1016/j.jhep.2008.06.018
- Söderberg C, Stål P, Askling J et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51:595. doi: 10.1002/hep.23314
- Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol. 2012;10:646. doi: 10.1016/j.cgh.2011.12.039
- Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107:1103. doi: 10.1016/0270-9139(95)90482-4
- Fracanzani AL, Valenti L, Bugianesi E et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48:792. doi: 10.1002/hep.22429
- Mofrad P, Contos MJ, Haque M et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37:1286. doi: 10.1053/jhep.2003.50229
- Диагностика и лечение неалкогольной жировой болезни печени. Методические рекомендации для врачей. Под ред. Ивашкина В.Т. 2015.
- Kowdley KV, Belt P, Wilson LA et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012;55:77. doi: 10.1002/hep.24706
- Pimentel CF, Jiang ZG, Otsubo T, Feldbrügge L, Challies TL, Nasser I, Robson S, Afdhal N, Lai M. Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH. Dig Dis Sci. 2015 Oct 13. doi: 10.1007/s10620-015-3916-1
- Hernaez R, Lazo M, Bonekamp S et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54:1082. doi: 10.1002/hep.24452
- Rofsky NM, Fleishaker H. CT and MRI of diffuse liver disease. Semin Ultrasound. CT MR 1995;16:16. doi: 10.1016/0887-2171(95)90012-8
- Froehlich F, Lamy O, Fried M, Gonvers JJ. Practice and complications of liver biopsy. Results of a nationwide survey in Switzerland. Dig Dis Sci. 1993;38:1480. doi: 10.1007/bf01308607
- Dunn W, Angulo P, Sanderson S et al. Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology. 2006;131:1057. doi: 10.1053/j.gastro.2006.08.020
- Food Drug Administration. Accessed July 29, 2015. Available et: http://www.accessdata.fda.gov/cdrh_docs/pdf12/K123806.pdf
- Koplay M, Sivri M, Erdogan H, Nayman A. Importance of imaging and recent developments in diagnosis of nonalcoholic fatty liver disease. World J Hepatol. 2015;7(5):769-776. doi: 10.4254/wjh.v7.i5.769
- Parkes J, Guha IN, Roderick P, Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol. 2006;44:462. doi: 10.1016/j.jhep.2005.10.019
- Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313. doi: 10.1002/hep.20701
- Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol. 1991;12:224. doi: 10.1016/0168-8278(91)90942-5
- Athyros VG, Tziomalos K, Gossios TD et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010;376:1916. doi: 10.12968/bjca.2011.6.2.94a
- Rakoski MO, Singal AG, Rogers MA, Conjeevaram H. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2010; 32:1211. doi: 10.1111/j.1365-2036.2010.04467.x
- Merat S, Malekzadeh R, Sohrabi MR et al. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatol. 2003;38:414. doi: 10.1016/s0168-8278(02)00441-5
- Zelber-Sagi S, Kessler A, Brazowsky E et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006;4:639. doi: 10.1016/j.cgh.2006.02.004
- Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology. 2009;49:80. doi: 10.1002/hep.22575
- Abdelmalek MF, Sanderson SO, Angulo P et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology. 2009;50:1818. doi: 10.1002/hep.23239
- Dufour JF, Oneta CM, Gonvers JJ et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2006;4:1537. doi: 10.1016/j.cgh.2006.09.025
- Pietu F, Guillaud O, Walter T et al. Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: long-term results. Clin Res Hepatol Gastroenterol. 2012;36:146. doi: 10.1016/j.clinre.2011.10.011
- Leuschner UF, Lindenthal B, Herrmann G et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology. 2010; 52:472. doi: 10.1002/hep.23727
- Foster T, Budoff MJ, Saab S et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol. 2011;106:71. doi: 10.1038/ajg.2010.299
- Zein CO, Yerian LM, Gogate P et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology. 2011;54:1610. doi: 10.1002/hep.24544
- Parker HM, Johnson NA, Burdon CA et al. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;56:944. doi: 10.1016/j.jhep.2011.08.018
- Safadi R, Konikoff FM, Mahamid M et al. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12:2085. doi: 10.1016/j.cgh.2014.04.038
- Neuschwander-Tetri BA, Loomba R, Sanyal AJ et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956. doi: 10.1016/s0140-6736(14)61933-4
- Mavin Macauley, Kieren G. Hollingsworth, Fiona E. Smith, Peter E. Thelwall, Ahmad Al-Mrabeh, Anja Schweizer, James E. Foley, Roy Taylor. Effect of Vildagliptin on Hepatic Steatosis. Jcem.endojournals.org. J Clin Endocrinol Metab. 2015;100(4): 1578-1585. doi: 10.1210/jc.2014-3794